This study showed that an increased expression of the complex I inhibitor NDUFA4L2 led to reduced ROS production and rendered HCC cells resistant to sorafenib, a first-line medication for advanced HCC.35 The gene discussed is COXFA4L2; the disease is hepatocellular carcinoma.